Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results
Andrea Lombardi, Giorgio Bozzi, Riccardo Ungaro, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

The use of RNA-based treatments in the field of cancer immunotherapy
Mohammad Chehelgerdi, Matin Chehelgerdi
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 82
mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
Miriam Echaide, Luisa Chocarro, Ana Bocanegra, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5944-5944
Open Access | Times Cited: 52
From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 90
Public Knowledge, Attitude, and Perception towards COVID-19 Vaccination in Saudi Arabia
Salman Mohammed Al-Zalfawi, Syed Imam Rabbani, Syed Mohammed Basheeruddin Asdaq, et al.
International Journal of Environmental Research and Public Health (2021) Vol. 18, Iss. 19, pp. 10081-10081
Open Access | Times Cited: 57
Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal vaccine strategies
Sodiq Ayobami Hameed, Stéphane Paul, Giann Kerwin Y. Dellosa, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 41
Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single-centre cohort study
Andrea Lombardi, Giacomo M. Butta, Lorena Donnici, et al.
The Lancet Regional Health - Europe (2021) Vol. 13, pp. 100287-100287
Open Access | Times Cited: 50
Putative Role of Vitamin D for COVID-19 Vaccination
Sheng-Kang Chiu, Kuo‐Wang Tsai, Chia‐Chao Wu, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8988-8988
Open Access | Times Cited: 45
COVID‑19 vaccination and IgG and IgA antibody dynamics in healthcare workers
Sabina Zurac, Luciana Nichita, Bogdan Mateescu, et al.
Molecular Medicine Reports (2021) Vol. 24, Iss. 2
Open Access | Times Cited: 44
Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2
Douglas F. Lake, Alexa J. Roeder, Erin Kaleta, et al.
Journal of Clinical Virology (2021) Vol. 145, pp. 105024-105024
Open Access | Times Cited: 43
SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations
Elizabeth M. Anderson, Shuk Hang Li, Moses Awofolaju, et al.
Cell Reports (2022) Vol. 41, Iss. 3, pp. 111496-111496
Open Access | Times Cited: 36
Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination
Nuchjira Takheaw, Chalerm Liwsrisakun, Warawut Chaiwong, et al.
Diagnostics (2022) Vol. 12, Iss. 6, pp. 1315-1315
Open Access | Times Cited: 29
Electrochemical Immunosensors Based on Zinc Oxide Nanorods for Detection of Antibodies Against SARS-CoV-2 Spike Protein in Convalescent and Vaccinated Individuals
Freddy A. Nunez, Ana Cristina Honorato de Castro, Vivian L. de Oliveira, et al.
ACS Biomaterials Science & Engineering (2022) Vol. 9, Iss. 1, pp. 458-473
Closed Access | Times Cited: 26
A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens
Shobha Upreti, Mukesh Samant
Pharmaceutical Research (2022) Vol. 39, Iss. 9, pp. 2119-2134
Open Access | Times Cited: 25
Chemically Modified mocRNAs for Highly Efficient Protein Expression in Mammalian Cells
Abhishek Aditham, Hailing Shi, Jianting Guo, et al.
ACS Chemical Biology (2022) Vol. 17, Iss. 12, pp. 3352-3366
Open Access | Times Cited: 24
The Beneficial Effect of the COVID-19 Vaccine Booster Dose among Healthcare Workers in an Infectious Diseases Center
Agata Skrzat‐Klapaczyńska, Carlo Bieńkowski, Justyna D. Kowalska, et al.
Vaccines (2022) Vol. 10, Iss. 4, pp. 552-552
Open Access | Times Cited: 22
Seroconversion after coronavirus disease 2019 vaccination in patients with immune deficiency
Jacqueline D. Squire, Avni Y. Joshi
Annals of Allergy Asthma & Immunology (2021) Vol. 127, Iss. 3, pp. 383-384
Open Access | Times Cited: 32
SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
Andrea Lombardi, Dario Consonni, Massimo Oggioni, et al.
Journal of Infection and Public Health (2021) Vol. 14, Iss. 8, pp. 1120-1122
Open Access | Times Cited: 31
SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines
Thomas E. Hickey, Troy J. Kemp, Jimmie Bullock, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 11
The Immune Response to SARS-CoV-2 and Variants of Concern
Elham Siasi Torbati, Kurt L. Krause, James E. Ussher
Viruses (2021) Vol. 13, Iss. 10, pp. 1911-1911
Open Access | Times Cited: 26
Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination
Raquel Guiomar, Ana João Santos, Aryse Martins Melo, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 154-154
Open Access | Times Cited: 16
A Systematic Review on the Safety and Efficacy of COVID-19 Vaccines Approved in Saudi Arabia
Thekra Ali Alhandod, Syed Imam Rabbani, Mansour Almuqbil, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 281-281
Open Access | Times Cited: 10
Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study
Xavier Sáez‐Llorens, Claudio F. Lanata, Elaine Aranguren, et al.
Vaccine X (2022) Vol. 11, pp. 100189-100189
Open Access | Times Cited: 15
New Generation Vaccines for COVID-19 Based on Peptide, Viral Vector, Artificial Antigen Presenting Cell, DNA or mRNA
Marzieh Rezaei, Mahboobeh Nazari
Avicenna Journal of Medical Biotechnology (2022)
Open Access | Times Cited: 13
Induction of humoral and cellular immune responses to COVID‐19 mRNA and vector vaccines: A prospective cohort study in Bulgarian healthcare workers
Maria Nikolova, Yana Todorova, Radoslava Emilova, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 5, pp. 2008-2018
Open Access | Times Cited: 11
Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice
Ki‐Hye Kim, Noopur Bhatnagar, Subbiah Jeeva, et al.
Vaccines (2021) Vol. 9, Iss. 4, pp. 316-316
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top